Athersys, Inc. announced the appointment of Daniel A. Camardo as the company's Board of Directors, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and biotech executive with more than 25 years of commercial leadership experience. Mr. Camardo currently serves as Executive Vice President and Head of the Rare Disease and Inflammation Business Units and President, U.S. at Horizon Therapeutics (Horizon), where he has led a broad commercial transformation and built out new capabilities to support a portfolio of products in the rare disease and specialty medicines space.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0033 USD | 0.00% |
|
+6.45% | -83.50% |
06-16 | Motion for Case Conversion Filed by Athersys, Inc. | CI |
04-11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
1st Jan change | Capi. | |
---|---|---|
-83.50% | 204K | |
+16.23% | 122B | |
+17.52% | 114B | |
+19.62% | 25.71B | |
-25.80% | 19.02B | |
-20.21% | 15.83B | |
-20.35% | 15.32B | |
-47.37% | 14.88B | |
+59.93% | 14.82B | |
+4.83% | 14.1B |
- Stock Market
- Equities
- ATHXQ Stock
- News Athersys, Inc.
- Athersys, Inc. Appoints Daniel A. Camardo to the Board of Directors, Effective February 14, 2022